オレゴンにおける胃癌の臨床試験
オレゴン内の拠点で、胃癌に関する14件の研究が参加者を募集しています。
オレゴン内の都市
公式研究テキスト（英語）
Studying the PAGODA Algorithm for Chemotherapy Dose Changes to Prevent Unplanned Treatment Delays
- Saint Alphonsus Cancer Care Center-Baker City, Baker City
- Saint Alphonsus Cancer Care Center-Ontario, Ontario
被験者募集中健康なボランティア歓迎
18歳以上 · 全性別 · 2026/10/02更新 · NCT07283939Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
- Saint Alphonsus Cancer Care Center-Baker City, Baker City
- Saint Charles Health System, Bend
- Clackamas Radiation Oncology Center, Clackamas
- 他7件
被験者募集中観察研究健康なボランティア歓迎
40歳〜75歳 · 全性別 · 2026/10/02更新 · NCT05334069A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Nivolumab in Combination With Chemotherapy in Participants With Previously Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma (ROSETTA Gastric-204)
- Oncology Associates Of Oregon, Pc, Eugene
- Northwest Cancer Specialists, P.C., Portland
被験者募集中第2/3相
18歳以上 · 全性別 · 2026/09/30更新 · NCT07221149A Phase 1, First-in-Human (FIH), Open-Label, Dose-Escalation and Dose Expansion Study of the Peptide Drug Conjugate (PDC), TS-104, as a Monotherapy in Subjects With Select Advanced Solid Tumors
- Site 02, Portland
被験者募集中第1相
18歳以上 · 全性別 · 2026/09/30更新 · NCT07814248Phase 3 Study of Cadonilimab Combined With Chemotherapy vs Chemotherapy in Combination With or Without Nivolumab for the 1L Treatment of Participants With HER2-negative, Previously Untreated, Unresectable or Metastatic Gastric/GEJ Adenocarcinoma
- Oregon Health and Science University, Portland
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/29更新 · NCT07700979Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors
- Providence Portland Medical Center, Portland
被験者募集中第1相
18歳以上 · 全性別 · 2026/09/10更新 · NCT06293898A Phase 1/1b Study of IAM1363 in HER2 Cancers
- Providence Cancer Institute, Portland
被験者募集中第1相
18歳以上 · 全性別 · 2026/09/09更新 · NCT06253871Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2
- Research Site, Portland
- Research Site, Portland
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/09更新 · NCT07431281A Study of MGC026 in Participants With Advanced Solid Tumors
- Providence Cancer Institute, Portland
被験者募集中第1相
18歳以上 · 全性別 · 2026/08/11更新 · NCT06242470Study of TDXd, Chemotherapy, Pembrolizumab, and Trastuzumab in First-Line Metastatic HER2-Positive Gastric or Gastroesophageal Junction Cancer
- Providence Portland Medical Center, Portland
被験者募集中第3相
18歳以上 · 全性別 · 2026/08/10更新 · NCT06731478Study of Orally Administered MOMA-341 in Participants With Advanced or Metastatic Solid Tumors
- Investigative Site #121, Portland
被験者募集中第1相
18歳以上 · 全性別 · 2026/07/23更新 · NCT06974110A Study of Sigvotatug Vedotin in Advanced Solid Tumors
- Providence Cancer Institute Franz Clinic, Portland
- Providence Oncology and Hematology Care Clinic - Westside, Portland
- Providence St. Vincent Medical Center- Investigational Drug Services, Portland
- 他1件
被験者募集中第1相
18歳以上 · 全性別 · 2026/07/06更新 · NCT04389632cfDNA Assay Prospective Observational Validation for Early Cancer Detection and Minimal Residual Disease
- Oregon Health Sciences University, Portland
被験者募集中観察研究健康なボランティア歓迎
40歳以上 · 全性別 · 2026/01/20更新 · NCT05366881SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
- Massive Bio SYNERGY-AI site, Portland
被験者募集中観察研究
全年齢 · 全性別 · 2025/10/28更新 · NCT03452774ClinicalTrials.govより、2026/10/05時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。